Transgene Sa Stock Performance
| TRGNF Stock | USD 1.59 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Transgene are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Transgene SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Transgene is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 5.3 M | |
| Total Cashflows From Investing Activities | 16.8 M |
Transgene |
Transgene Relative Risk vs. Return Landscape
If you would invest 159.00 in Transgene SA on December 20, 2024 and sell it today you would earn a total of 0.00 from holding Transgene SA or generate 0.0% return on investment over 90 days. Transgene SA is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Transgene, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Transgene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Transgene's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Transgene SA, and traders can use it to determine the average amount a Transgene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TRGNF |
Based on monthly moving average Transgene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Transgene by adding Transgene to a well-diversified portfolio.
Transgene Fundamentals Growth
Transgene Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Transgene, and Transgene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Transgene Pink Sheet performance.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 152.15 M | |||
| Shares Outstanding | 100.2 M | |||
| Price To Earning | (7.42) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 10.71 X | |||
| Revenue | 9.99 M | |||
| EBITDA | (16.55 M) | |||
| Cash And Equivalents | 49.57 M | |||
| Cash Per Share | 0.50 X | |||
| Debt To Equity | 0.25 % | |||
| Book Value Per Share | 0.55 X | |||
| Cash Flow From Operations | (31.94 M) | |||
| Earnings Per Share | (0.23) X | |||
| Total Asset | 101.84 M | |||
| Retained Earnings | (500 M) | |||
| Current Asset | 51 M | |||
| Current Liabilities | 24 M | |||
About Transgene Performance
By analyzing Transgene's fundamental ratios, stakeholders can gain valuable insights into Transgene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Transgene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Transgene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people.Things to note about Transgene SA performance evaluation
Checking the ongoing alerts about Transgene for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Transgene SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Transgene SA generated a negative expected return over the last 90 days | |
| Transgene SA may become a speculative penny stock | |
| Transgene SA has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 9.99 M. Net Loss for the year was (19.54 M) with loss before overhead, payroll, taxes, and interest of (15.87 M). | |
| Transgene SA has accumulated about 49.57 M in cash with (31.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. |
- Analyzing Transgene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Transgene's stock is overvalued or undervalued compared to its peers.
- Examining Transgene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Transgene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Transgene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Transgene's pink sheet. These opinions can provide insight into Transgene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Transgene Pink Sheet analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |